Polyclonal antibodies step out of the shadows

Article Abstract:

Biotech companies are addressing the problem of inability of monoclonals to address targets that mutate or require binding at multiple sites through two radically different approaches. The first and most advanced involves isolating the variable light and heavy (VL-VH) region of gene pairs from antibody-producing plasma cells and second involves the application of gene targeting/nuclear transfer technology in animals to replace partially or completely animal immunoglobulin genes with analogous genes from humans.

Biological products exc. diagnostic, Polyclonal Antibodies, Medarex Inc., MEDX, Hematech Inc., Therapeutic Human Polyclonals Inc.

---

GlaxoSmithKline cancer drug threatens Herceptin market

Article Abstract:

The first therapy for breast cancer, Genentech's Herceptin (trastuzumab), will face direct competition from GlaxoSmithKline (GSK) which is coming out with a novel drug GW 572016 (lapatinib), the only dual-action tyrosine kinase inhibitor in phase 3 trials. Lapatinib comes in the form of a tablet to be taken orally once a day, which can be also be used in combination with traditional chemotherapy and as a monotherapy, could supplant Herceptin.

United Kingdom, Anticancer Drugs, Chemotherapeutic Drugs, Antineoplastic agents, GlaxoSmithKline PLC, Antimitotic agents

---

Supreme Court boosts licensees in biotech patent battles

Article Abstract:

The impact of the U.S. Supreme Court's decision regarding the patents on the biotech industry, licensees and patent holders is discussed. The decision will be depending on how broadly lower courts interpret it in many of the patent lawsuits.

Legal issues & crime, Patents & copyrights, Legal/Government Regulation, Licenses, Patents & Trademarks, Company legal issue, Cases, Intellectual property, Genentech Inc., MedImmune Inc., DNA, Case overview

Similar abstracts:

• Abstracts: Delisting threat looms large on biotech front. When less is more. Making it in the biotech business
• Abstracts: Shift toward early-stage deals favors bioteochs. Public biotech 2006- the numbers
• Abstracts: Mind the (biomedical funding) gap. The importance of angels in starting a US biotech venture. Biotech venture capital-it's not too late to be early
• Abstracts: Determinants of voluntary Internet financial reporting by local government authorities. Disclosure timing: determinants of quarterly earnings release dates
• Abstracts: GAO finds army trucks not armored for lack of money. Army likely to increase use of systems integration contractors

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.